US Patent No: 4,259,314

Number of patents in Portfolio can not be more than 2000

Method and composition for the preparation of controlled long-acting pharmaceuticals

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

A method and composition for the preparation of controlled long-acting pharmaceuticals using a dry carrier or base material comprising an effective amount of hydroxypropyl methylcellulose and hydroxypropyl cellulose suitable for use with both hygroscopic and non-hygroscopic materials. The controlled long-acting products of the invention are suitable for use in the form of lozenges, buccal tablets, oral tablets or suppositories.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • Assignment data not available. Check PTO

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Lowey, Hans 7 Deerfield La., Mamaroneck, NY 10543 4 192

Cited Art Landscape

  • No Cited Art to Display

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (11)
* 4,680,323 Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration 37 1983
* 4,775,535 Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics 22 1986
* 4,855,143 Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics 22 1988
6,264,974 Buccal and sublingual administration of physostigmine 5 1998
* 2003/0171,419 Pharmaceutical compositions comprising fluvastatin 0 2002
* 2004/0096,500 Controlled release oxycodone compositions 28 2003
* 2004/0185,098 Controlled release oxycodone compositions 18 2004
* 2006/0057,165 Clostridium botulinum toxin formulation and method for reducing weight 8 2005
* 2006/0099,263 Antidepressant dosage form 0 2005
* 2006/0127,474 Pharmaceutical compositions comprising fluvastatin 0 2006
* 2007/0225,341 Nicotinic Acid Compositions For Treating Hyperlipidemia and Related Methods Therefor 1 2007
 
RECKITT BENCKISER LLC (12)
6,372,252 Guaifenesin sustained release formulation and tablets 14 2000
6,955,821 Sustained release formulations of guaifenesin and additional drug ingredients 9 2002
* 2003/0049,318 Sustained release formulations of guaifenesin and additional drug ingredients 10 2002
7,985,420 Sustained release of guaifenesin combination drugs 0 2003
7,838,032 Sustained release of guaifenesin 2 2003
* 2004/0022,851 Sustained release of guaifenesin combination drugs 6 2003
* 2004/0018,233 Sustained release of guaifenesin 5 2003
8,012,504 Sustained release of guaifenesin combination drugs 1 2003
* 2003/0215,508 Sustained release of guaifenesin combination drugs 7 2003
7,985,421 Sustained release formulations of guaifenesin and additional drug ingredients 0 2005
* 2005/0276,852 Sustained release formulations of guaifenesin and additional drug ingredients 19 2005
* 2011/0052,689 SUSTAINED RELEASE OF GUAIFENESIN 0 2010
 
Unitel Technologies, Inc. (3)
6,821,532 Methods and compositions for the treatment of benign prostatic hypertrophy 2 2001
6,733,796 Methods and compositions for the treatment of benign prostatic hypertrophy 3 2002
* 2003/0096,009 Methods and compositions for the treatment of benign prostatic hypertrophy 0 2002
 
ELAN CORPORATION, PLC (1)
* 6,110,494 Cisapride mini-tablet formulations 8 1997
 
Christian Hansen A/S (2)
* 5,645,830 Lactobacillus and skim milk compositions and methods for preventing microbial urogenital infections 14 1994
* 6,004,551 Lactobacillus and skim milk pharmaceutical compositions 11 1996
 
NOVARTIS AG (4)
6,242,003 Organic compounds 4 2000
6,432,447 Organic compounds 1 2001
8,303,987 Pharmaceutical compositions comprising fluvastatin 0 2010
* 2010/0303,919 PHARMACEUTICAL COMPOSITIONS COMPRISING FLUVASTATIN 0 2010
 
JASON ENTERPRISES INC. (1)
* 2003/0167,556 Methods and devices for transdermal delivery of anti-aging compounds for treatment and prevention of facial or neck skin aging 20 2002
 
PALMETTO PHARMACEUTICALS, LLC (6)
* 2011/0196,039 Controlled release arginine formulations 0 2001
7,381,731 Pharmaceutical composition comprising citrulline 0 2004
* 2004/0242,682 Compositions comprising arginine and nitrates 1 2004
* 2004/0186,164 Pharmaceutical composition comprising citrulline 0 2004
* 2005/0085,548 Method and formulation for treating vascular disease 0 2004
* 2011/0212,174 CONTROLLED RELEASE ARGININE FORMULATIONS 0 2011
 
FUJISAWA PHARMACEUTICAL CO., LTD. (1)
* 4,654,206 Fast release solid preparation of dihydropyridine a compound 14 1984
 
KOS LIFE SCIENCES, INC. (1)
7,998,506 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor 0 2003
 
Actavis Group HF (1)
* 2004/0086,566 Waxy matrix dosage forms 1 2002
 
HOFFMANN-LA ROCHE INC. (1)
* 5,393,765 Pharmaceutical compositions with constant erosion volume for zero order controlled release 36 1993
 
KOS LIFE SCIENCE LLC (2)
* 6,080,428 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor 5 1995
* 6,129,930 Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night 11 1997
 
EFFCON LABORATORIES, INC. (1)
6,214,381 Methazolamide composition and method of use 0 1998
 
ABBOTT RESPIRATORY LLC (3)
6,818,229 Intermediate release nicotinic acid compositions for treating hyperlipidemia 9 1997
6,746,691 Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics 9 1997
6,676,967 Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia 9 1997
 
ASTELLAS PHARMA INC. (1)
* 4,916,138 Solid dispersion composition of FR-900506 substance 58 1988
 
NIPPON SODA CO., LTD. (1)
8,617,596 Sustained-release tablet production process 0 2007
 
Theracos, Inc. (1)
* 2005/0143,350 Combination drug therapy to treat obesity 3 2004
 
Plastic Dress-Up Co. (1)
* 5,895,663 Pseudoephedrine hydrochloride extended-release tablets 24 1997
 
FARVALSA A.G. (1)
* 4,837,032 Theophylline sustained release tablet 18 1986
 
HANALL BIOPHARMA CO., LTD. (1)
* 2011/0038,931 COMPOSITE PREPARATION 0 2009
 
GLOBALFOUNDRIES INC. (1)
* 2008/0055,036 Electrical component tuned by conductive layer deletion 1 2006
 
ANESTIC APS (1)
* 2004/0047,910 Suppository and composition comprising at least one polyethylene glycol 13 2003
 
Shionogi Inc. (3)
* 2009/0087,490 EXTENDED RELEASE FORMULATION AND METHOD OF TREATING ADRENERGIC DYSREGULATION 1 2008
* 2010/0209,510 Extended Release Formulation and Method of Treating Adrenergic Dysregulation 0 2009
7,884,122 Extended release formulation and method of treating adrenergic dysregulation 1 2009
 
FOREST LABORATORIES, INC. (6)
* 4,369,172 Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose 237 1981
* 4,389,393 Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose 288 1982
* 4,795,327 Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants 41 1984
* 4,540,566 Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose 71 1984
* 4,849,229 Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants 30 1988
* 4,983,398 Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates 30 1988
 
SANDOZ LTD. (1)
* 5,069,911 Pharmaceutical 9,10-dihydrogenated ergot alkaloid containing compositions 4 1990
 
FABRE-KRAMER PHARMACEUTICALS, INC. (1)
* 2006/0134,193 Method to improve pharmaceutical tablets having a matrix of cellulose ether 0 2003
 
NASTECH PHARMACEUTICAL COMPANY, INC. (3)
* 2005/0143,303 Intranasal administration of glucose-regulating peptides 23 2004
* 2008/0318,837 Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide 29 2006
* 2008/0234,200 METHOD OF TREATMENT OF A METABOLIC DISEASE USING INTRANASAL ADMINISTRATION OF EXENDIN PEPTIDE 2 2008
 
RANBAXY LABORATORIES LIMITED (2)
6,960,356 Orally administered drug delivery system providing temporal and spatial control 10 1999
* 2006/0147,530 Sustained release compositions containing alfuzosin 1 2003
 
CONCORDIA PHARMACEUTICALS, INC. (3)
* 5,484,607 Extended release clonidine formulation 32 1993
* 5,869,100 Extended release clonidine formulation (tablet) 23 1997
* 6,030,642 Extended release clonidine formulation (capsule) 22 1997
 
RANBAXY RESEARCH LABORATORIES (1)
* 5,948,440 Modified release matrix formulation of cefaclor and cephalexin 14 1997
 
Key Pharmaceuticals, Incorporated (3)
* 4,508,702 Sustained release aspirin 11 1984
* 4,555,399 Aspirin tablet 41 1984
* 4,634,587 Sustained release quinidine dosage form 22 1984
 
BIOVASCULAR, INC. (1)
9,040,483 Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor 0 2012
 
VALEANT INTERNATIONAL BERMUDA (1)
6,893,661 Controlled release formulations using intelligent polymers 19 1998
 
ALZA CORPORATION (5)
* 4,786,503 Dosage form comprising parallel lamine 35 1987
* 4,851,232 Drug delivery system with means for obtaining desirable in vivo release rate pattern 48 1987
* 4,946,685 Cellulosic dosage form 59 1988
* 5,204,116 Dosage form providing immediate therapy followed by prolonged therapy 22 1991
* 5,338,550 Stereoisomer therapy 8 1992
 
PENWEST PHARMACEUTICALS CO. (7)
* 4,994,276 Directly compressible sustained release excipient 70 1988
* 5,128,143 Sustained release excipient and tablet formulation 64 1990
* 5,135,757 Compressible sustained release solid dosage forms 46 1991
* 5,169,639 Controlled release verapamil tablets 34 1991
* 5,472,711 Agglomerated hydrophilic complexes with multi-phasic release characteristics 42 1992
* 5,478,574 Agglomerated hydrophilic complexes with multi-phasic release characteristics 28 1993
* 5,670,168 Agglomerated hydrophilic complexes with multi-phasic release characteristics 29 1996
 
EURO-CELTIQUE S.A. (9)
* 4,366,310 Controlled release compositions 74 1980
* 5,891,471 Pharmaceutical multiparticulates 133 1996
* 5,849,240 Method of preparing sustained release pharmaceutical compositions 149 1996
* 5,843,480 Controlled release diamorphine formulation 107 1996
* 6,068,855 Pharmaceutical composition containing a fusible carrier and method for producing the same 83 1997
* 5,965,163 Substained release compositions and a method of preparing pharmaceutical compositions 142 1997
* 6,162,467 Sustained release compositions and a method of preparing pharmaceutical compositions 114 1999
8,557,286 Method for producing a water-insoluble amorphous or partially amorphous controlled release matrix 0 2000
* 2004/0170,680 Once-a-day oxycodone formulations 63 2004
 
SCHERING CORPORATION (3)
* 4,601,894 Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate 29 1985
* 4,695,591 Controlled release dosage forms comprising hydroxypropylmethylcellulose 46 1985
* 4,657,757 Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate 14 1985
 
Purdue Pharma L.P. (10)
* 5,965,161 Extruded multi-particulates 164 1994
* 5,958,452 Extruded orally administrable opioid formulations 193 1997
6,335,033 Melt-extrusion multiparticulates 113 1999
6,261,599 Melt-extruded orally administrable opioid formulations 158 1999
6,743,442 Melt-extruded orally administrable opioid formulations 73 2001
6,706,281 Melt-extrusion multiparticulates 77 2002
* 2005/0089,568 Melt-extruded orally administrable opioid formulations 31 2003
7,510,727 Melt-extrusion multiparticulates 8 2003
* 2010/0092,570 CONTROLLED RELEASE OXYCODONE COMPOSITIONS 10 2009
* 2010/0034,876 CONTROLLED RELEASE OXYCODONE COMPOSITIONS 10 2009
 
THE DOW CHEMICAL COMPANY (3)
* 4,695,464 Sustained release dosage form based on highly plasticized cellulose ether gels 30 1984
* 4,678,516 Sustained release dosage form based on highly plasticized cellulose ether gels 63 1984
* 4,734,285 Sustained release compositions 39 1985
 
Aktiebolaget Hassle (1)
* 4,942,040 Pharmaceutical preparation and a process for its preparation 38 1988
 
DRUGTECH CORPORATION (1)
* 5,445,829 Extended release pharmaceutical formulations 184 1992
 
TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (1)
6,337,091 Matrix for controlled delivery of highly soluble pharmaceutical agents 16 1997
 
Alpharx Inc. (1)
* 2005/0037,073 Solid self-emulsifying dosage form for improved delivery of poorly soluble hydrophobic compounds and the process for preparation thereof 5 2004
 
E. R. Squibb & Sons, Inc. (4)
* 4,505,890 Controlled release formulation and method 23 1983
* 4,610,870 Controlled release formulation 93 1984
* 4,666,705 Controlled release formulation 62 1985
* 4,756,911 Controlled release formulation 97 1986
 
Supernus Pharmaceuticals, Inc. (2)
8,709,476 Compositions of quaternary ammonium compounds containing bioavailability enhancers 0 2004
* 2006/0210,625 Sustained release of positively charged pharmacologically active molecules from a matrix containing polymers with polarized oxygen atoms 3 2004
 
Mead Johnson & Company (2)
* 4,465,660 Sustained release tablet containing at least 95 percent theophylline 26 1982
* 4,547,358 Sustained release tablet containing at least 95 percent theophylline 12 1984
 
NAPP PHARMACEUTICAL GROUP LIMITED (5)
* 5,591,452 Controlled release formulation 101 1994
6,326,027 Controlled release formulation 94 1995
6,254,887 Controlled release tramadol 96 1996
7,074,430 Controlled release tramadol tramadol formulation 28 2001
* 2006/0269,603 Controlled release tramadol formulations 20 2006
 
NOSTRUM PHARMACEUTICALS, INC. (1)
7,179,486 Process for preparing sustained release tablets 8 2001
 
PURDUE PHARMA COMPANY, THE (2)
* 2006/0057,210 Controlled release oxycodone compositions 14 2005
* 2008/0075,781 Controlled release oxycodone compositions 5 2007
 
SYNGENTA LIMITED (1)
* 5,948,437 Pharmaceutical compositions using thiazepine 20 1997
 
TCD ROYALTY SUB, LLC (6)
7,781,448 Once daily dosage forms of trospium 0 2007
7,781,449 Trospium chloride treatment method 0 2007
7,763,635 Once daily dosage forms of trospium 6 2007
7,759,359 Method of treating bladder dysfunction with once-a-day trospium salt formulation 0 2007
* 2010/0221,355 PHARMACEUTICAL COMPOSITION FOR ONCE-A-DAY ORAL ADMINISTRATION OF TROSPIUM CHLORIDE 0 2010
* 2010/0221,353 Pharmaceutical Composition For Once-A-Day Administration of Trospium Chloride 0 2010
 
SHIN-ETSU CHEMICAL CO., LTD. (1)
* 5,476,668 Base for film-coating pharmaceuticals and method for preparing same 5 1993
 
SOCIETE CIVILE DITE MEDIBREVEX" (1)
* 5,061,493 Galenical forms of corticoids for administration perlingually and sublingually and process for their preparation 2 1988
 
HERCULES INCORPORATED (2)
* 5,480,984 Process of preparing high solids low viscosity polysaccharides 6 1992
6,210,710 Sustained release polymer blend for pharmaceutical applications 43 1997
 
Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. (1)
* 6,042,847 Three-phase pharmaceutical form with constant and controlled release of amorphous active ingredient for single daily application 47 1997
 
TAYLOR MADE GOLF COMPANY, INC. (1)
* 2008/0102,982 Golf club iron head 18 2007
 
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (1)
* 5,840,756 Pharmaceutical composition of L-DOPA ester 25 1996
 
TCF NATIONAL BANK (2)
* 5,126,145 Controlled release tablet containing water soluble medicament 122 1990
* 5,268,181 Method of using niacin to control nocturnal cholesterol synthesis 19 1992
* Cited By Examiner